This is an open access article which appeared in a journal published by Elsevier. This article is free for everyone to access, download and read.

Any restrictions on use, including any restrictions on further reproduction and distribution, selling or licensing copies, or posting to personal, institutional or third party websites are defined by the user license specified on the article.

For more information regarding Elsevier’s open access licenses please visit:

http://www.elsevier.com/openaccesslicenses
The ALFA project: A research platform to identify early pathophysiological features of Alzheimer’s disease

José Luis Molinuevo\textsuperscript{a,\ast}, Nina Gramunt\textsuperscript{a}, Juan Domingo Gispert\textsuperscript{a}, Karine Fauria\textsuperscript{a}, Manel Esteller\textsuperscript{b,c,d}, Carolina Minguillon\textsuperscript{a}, Gonzalo Sánchez-Benavides\textsuperscript{a}, Gema Huesa\textsuperscript{a}, Sebastián Morán\textsuperscript{b,c}, Rafael Dal-Re\textsuperscript{a}, Jordi Cami\textsuperscript{e,f,\ast}

\textsuperscript{a}Barcelonaβeta Brain Research Center, Barcelona, Spain
\textsuperscript{b}Epidogenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
\textsuperscript{c}Department of Physiological Sciences II, School of Medicine, University of Barcelona (UB), Barcelona, Spain
\textsuperscript{d}Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
\textsuperscript{e}Pascual Maragall Foundation, Barcelona, Spain
\textsuperscript{f}Universitat Pompeu Fabra, Barcelona, Spain

Abstract

Introduction: The preclinical phase of Alzheimer’s disease (AD) is optimal for identifying early pathophysiological events and developing prevention programs, which are shared aims of the ALFA project, including the ALFA registry and parent cohort and the nested ALFA+ cohort study.

Methods: The ALFA parent cohort baseline visit included full cognitive evaluation, lifestyle habits questionnaires, DNA extraction, and MRI. The nested ALFA+ study adds wet and imaging biomarkers for deeper phenotyping.

Results: A total of 2743 participants aged 45 to 74 years were included in the ALFA parent cohort. We show that this cohort, mostly composed of cognitively normal offspring of AD patients, is enriched for AD genetic risk factors.

Discussion: The ALFA project represents a valuable infrastructure that will leverage with different studies and trials to prevent AD. The longitudinal ALFA+ cohort will serve to untangle the natural history of the disease and to model the preclinical stages to develop successful trials.

Keywords: Alzheimer’s disease; Dementia; Cohort studies; Cognition; Prevention; Biomarkers; Risk factors

1. Introduction

The increase in average life expectancy that has occurred in developed countries during the last 50 years has been accompanied by an increment in the prevalence of age-associated disorders. Alzheimer’s disease (AD), more specifically, late-onset AD (LOAD) is the first cause of neurological disability in the elderly causing enormous social and economic burden in modern societies [1]. Currently, >45 million people suffer from dementia worldwide and with the progressive aging of the population, this figure is expected to increase to up to 130 million in 2050 [2]. Despite having described the AD clinicopathological hallmarks over a century ago, its precise etiology remains unknown. It is noteworthy that, to date, all clinical trials evaluating disease-modifying drugs performed have failed [3].

In the last decade, several \textit{in vivo} AD biomarkers, such as β-amyloid (Aβ) and tau concentration in cerebrospinal fluid (CSF [4]), hippocampal atrophy [5,6], temporoparietal hypometabolism [7,8], and cerebral amyloid deposition measured by positron emission tomography (PET [9,10]), have been extensively characterized. The results of these
studies show that AD pathology develops for several years or even decades before clinical symptoms appear; this silent asymptomatic period of the disease is referred to as the preclinical stage of AD [11]. The detection of this preclinical stage opens up novel opportunities for the development of new therapeutic strategies. If new treatments capable of delaying the evolution of the disease and the appearance of dementia emerge in the next years, they will be especially useful during the preclinical phase of the disease [12]. In fact, as AD burden increases with the aging of the population, a treatment capable of delaying the onset of dementia by only a few years would have a tremendous impact on the social cost of the disease. Indeed, it has been calculated that a delay in dementia’s onset of only 5 years could reduce a 33% of the economic cost of AD [13]. In this scenario, it has been hypothesized that, to increase the possibilities of success, drugs that have failed in trials performed on AD patients should be essayed in cognitively healthy subjects that are at elevated risk of developing AD. Even more, the preclinical stage could be the optimal timeframe to evaluate new therapeutic strategies directed against targets not only related to the amyloid cascade but also focused on delaying neuronal loss [14]. Moreover, interventional preventive strategies may help to better understand the relationship between the different medical, environmental, and genetic factors and the onset of symptoms.

The setup of preventive studies requires the identification of individuals with an increased risk of developing AD in the near future that are suitable to be recruited as asymptomatic subjects in clinical trials. With this in mind, a number of research projects have been designed and are currently ongoing such as the Wisconsin Registry for Alzheimer’s Prevention program [15], the Adult Children Study [16], and the more recently developed PREVENT programme [17] and the longitudinal cohort study of the European Prevention of Alzheimer’s Dementia (EPAD) project [18], among others.

Following the same rationale and aiming at increasing our knowledge of the pathophysiology and pathogenic factors emerging at early preclinical AD stages, the Barcelona-βeta Brain Research Center (BBRC) started the ALFA (for Alzheimer and Families) project for the prospective follow-up of a cohort of cognitively normal subjects, most of which are the offspring of AD patients. The ALFA project consists of the ALFA registry, the ALFA parent cohort, and the nested ALFA+ cohort study. The ALFA registry contains basic demographic data of persons willing to participate in future BBRC projects. The ALFA parent cohort is composed of cognitively normal participants aged between 45 and 74 years, who were administered a series of cognitive tests and from which we collected their clinical history and a description of AD risk-associated variables of the ALFA parent cohort participants at baseline are also presented.

2. Methods

2.1. The ALFA parent cohort

The ALFA parent cohort represents a research platform that will supply related studies such as the longitudinal ALFA+.

2.1.1. Inclusion and exclusion criteria

Inclusion criteria were being cognitively normal Spanish and/or Catalan-speaking persons aged between 45 and 74 years that agreed with the study procedures and tests: clinical interview and questionnaires associated to risk factors, cognitive tests, a blood sample extraction for DNA analysis, and MRI. Furthermore, a close relative was involved in the volunteer’s functional evaluation and both of them had to grant their consent. A high percentage of the individuals recruited were cognitively normal offspring of AD patients.

Exclusion criteria were (1) Cognitive performance falling outside the established cutoffs: Mini-Mental State Examination [19,20] (MMSE) < 26, or Memory Impairment Screen [21,22] (MIS) < 6, or Time-Orientation subtest of the Barcelona Test II [23] (TO-BTII) < 68, or semantic fluency [24,25] (animals; SF) < 12. (2) Clinical Dementia Rating scale [26]; CDR > 0. (3) Major psychiatric disorders (according to DSM-IV-TR) or diseases that could affect cognitive abilities (current major depression or general anxiety disorder, bipolar disorder, schizophrenia, and dementia). The Goldberg Anxiety and Depression Scale [27,28] (GADS) was used to screen for mood disorders. Whenever the scores were dubious, the rater assessed whether the subject met the DSM-IV-TR criteria for general anxiety disorder or major depressive episode and was excluded if this was the case. (4) Severe auditory and/or visual disorder, neurodevelopmental and/or psychomotor disorder. (5) Significant diseases that could currently interfere with cognition (renal failure on hemodialysis, liver cirrhosis, chronic lung disease with oxygen therapy, solid organ transplantation, fibromyalgia, active cancer in treatment, or any
other disease the investigator considered could affect the participant’s cognition). (6) Neurological disorders, such as Parkinson’s disease, stroke, epilepsy under treatment with frequent seizures (>1/month) in the past year, multiple sclerosis, or other serious neurological diseases. (7) Brain injury that could interfere with cognition: history of head trauma with parenchymal lesion or extraaxial macroscopic large vessel ischemic stroke or hemorrhagic stroke, brain surgery, brain tumors, or other causes that could generate acquired brain damage such as cerebral chemotherapy or radiotherapy, and, finally, (8) suspected pattern of family history of autosomal dominant AD: three affected individuals in two different generations with an onset before the age of 60 years. The ALFA study inclusion and exclusion criteria are listed in Table 1.

2.1.2. Baseline assessment

Recruited subjects were received at the BBRC, Barcelona, Spain, where they were evaluated by a trained neuropsychologist. Once the volunteer had given informed consent and the study inclusion criteria had been met, the subject’s medical history and a number of sociodemographic characteristics were recorded, and the cognitive assessment was performed. A study nurse was in charge of taking the subject’s blood pressure and height, weight, and waist diameter measurements as well as of obtaining a blood sample for further genetic characterization.

The baseline visit was structured as follows (Fig. 1A):

2.1.2.1. Revision of the study’s inclusion criteria

To ensure compliance with the study inclusion criteria, an initial evaluation of the volunteers’ neuropsychological status was performed through the screening tools mentioned above. Given the bilingual reality of the social context where the visit took place, participants were previously asked for their preferred language (Catalan or Spanish). A specific report on the screening results was given independently of whether the subject was eligible as an ALFA population member. The CDR was the last assessment tool at screening. In the case that the subject was previously excluded for any other reason, the functional assessment was performed through the IQCODE ([29,30] provided it is shorter and there will not be a follow-up of the volunteer), and the result was included in the delivered report (Fig. 1A). Subjects excluded due to cognitive or functional performance falling outside the established cutoffs were advised to visit their primary care physician if they had previously noticed a significant change in their everyday mental performance. Those excluded due to mood-related criteria were also recommended to ask for medical advice.

After initial cognitive, functional, and mood status evaluation, subjects were asked about their familiar and personal medical history with special emphasis on psychiatric and neurological disorders, and they were excluded if a condition that was incompatible with their inclusion in the study was detected.

2.1.2.2. Neuropsychological evaluation

After initial evaluation, eligible subjects were administered an experimental cognitive test battery for the potential detection of early impairment in longitudinal follow-ups. This battery assessed episodic verbal memory [the Memory Binding Test [31,32] (MBT)], psychomotor speed, visual processing, executive function, and non-verbal and verbal reasoning (Coding, Visual Puzzles, Digit Span, Matrix Reasoning, and Similarities of the WAIS IV [33]).

2.1.2.3. Sociodemographic data and medical history

Basic sociodemographic data were registered. All participants were asked about their familiar and personal medical history, and chronic medication use was recorded. Participants’ cognitive reserve was assessed with the administration of the Cognitive Reserve Questionnaire.

| Inclusion criteria | Exclusion criteria |
|--------------------|-------------------|
| Spanish and/or Catalan-speaking men and women | Cognitive: MMSE <26, MIS <6, SF <12, TO-BTII <68 |
| Aged between 45 and 74 years | CDR >0 |
| Agreement with study procedures and tests | Major psychiatric disorders (DSM-IV-TR) or diseases that could affect cognitive abilities |
| Involvement of a close relative for the participant’s functional evaluation | Severe auditory and/or visual, neurodevelopmental and/or psychomotor disorders, significant diseases that could interfere with cognition |
| | Neurological disorders |
| | Brain injury that could interfere with cognition |
| | Family history of AD with suspected autosomal dominant pattern |

Abbreviations: CDR, Clinical Dementia Rating scale; MMSE, Mini-Mental State Examination; MIS, Memory Impairment Screen; TO-BTII, Time-Orientation subtest of the Barcelona Test II; SF, Semantic Fluency.
consisting of 8 items, namely formal education, parental formal education, attendance to courses, occupation, musical education, languages spoken and frequency of reading, and cognitively stimulating activities.

2.1.2.4. Anthropometric measurements and blood sample extraction

Participants’ weight, height, blood pressure, and waist and hip circumference were measured. Their weight and height measurements were used to calculate their body mass index (BMI) that allows their categorization in BMI \( \leq 30 \) or BMI \( >30 \), cutoffs considered in the CAIDE (cardiovascular risk factors, aging, and incidence of dementia) dementia risk score [35]. Similarly, participants’ systolic blood pressure measurements allow their classification in two groups \((\leq 140 \text{ and } >140)\) that imply distinct degrees of risk.

A 10 mL of blood were obtained in an EDTA tube and centrifuged to separate the plasma from the cellular fraction. Both fractions were immediately stored at \(-20^\circ\text{C}\) at the

Fig. 1. Schematic representation of the ALFA parent cohort baseline visit and screening process. (A) Regardless of their eligibility to enter or not the ALFA parent cohort, all subjects assessed received a specific report on the screening results. (B) Cognitive eligibility was assessed by the administration of the cognitive screening tests (MMSE, MIS, TO-BTII, and SF). The Goldberg Anxiety and Depression Scale was used to screen for mood disorders.
2.1.3. Apolipoprotein E genotyping

Total DNA was obtained from the blood cellular fraction by proteinase K digestion followed by alcohol precipitation. Using the following primers (APOE-F 5'-TTGAAGGCTTA CAAAAGGAACCTG-3' and APOE-R 5'-CCGGGCTGCCCATT CTCTTCATCGG-3') samples were genotyped for two SNPs, rs429358 and rs7412, determining the possible APOE alleles: e1, rs429358 (C) + rs7412 (T); e2, rs429358 (T) + rs7412 (T); e3, rs429358 (T) + rs7412 (C); and e4, rs429358 (C) + rs7412 (C).

2.1.4. Other epidemiologic data collected

Additional information was obtained by means of self-reporting questionnaires. The EQ-5D-3L scale [36,37] was used to obtain the participants’ perceived quality of life; physical activity was measured with the Spanish short version of the Minnesota Short Form Physical Activity Questionnaire [38]; dietary habits were gathered by a 166-item food frequency questionnaire; alcohol, tobacco, and drug consumption were collected by a simplified version of the 2009 Spanish Ministry of Health National Plan on Drugs Questionnaire; sleeping habits questionnaire [39]; a revised version of the Eysenck personality questionnaire [40] (EPQ-R) was used to assess personality traits; and, finally, information related to social activity and religious practices was also gathered.

2.1.5. Data management and quality control

Data were systematically collected using two databases: one for the screening procedure that allowed the automatic creation of a report with the results (NeuroCog; www.neuro-cog.com), and the rest of the information was directly introduced in a data management system (OpenClinica; www.openclinica.com) that allowed the generation of reports for further analyses. Source documents (2095 of 3102, i.e., 67.5%) for the cognitive assessment were reintroduced in a data management system (OpenClinica; www.openclinica.com), and the rest of the information was directly entered into consideration. In addition, participants will be stratified by age and gender.

Data quality control was performed for all the visited cases using complete reports of incidences within both e-databases and compared to our personal registries. Queries were corrected using source data verification. Moreover, the whole data were thoroughly reviewed by the data management team in search of inconsistencies or missing information and corrective measures were undertaken whenever possible and/or necessary. Additionally, and throughout the whole study, research personnel received newsletters on a regular basis where, among other information, the most frequent errors and inconsistencies were highlighted and measures to avoid them were established.

2.1.6. Statistical analyses

The chi square goodness of fit test was used to assess for statically significant differences between the frequencies of the APOE genotypes between the parent ALFA cohort and those reported in control subjects in the AlzGene database (http://www.alzgene.org/meta.asp?geneID=83). The same test (chi square) was used to assess for significant differences in the prevalence of clinical features and midlife CAIDE dementia risk scores between ALFA parent cohort members and the general population [35,41]. SPSS 15.0 for Windows was used for all the analyses. Differences were considered to be significant at $P < .05$.

2.2. The ALFA+ study

A subset of participants of the ALFA parent cohort will be invited to join the ALFA+ study: a nested long-term longitudinal study aiming to understand the early pathophysiological changes of AD during its preclinical stage. The ALFA+ longitudinal cohort will include 440 individuals, which will be invited to participate based on their specific AD risk profile. This profile will be determined by an algorithm in which participants’ AD parental history and APOE status, verbal episodic memory score and CAIDE score will be taken into consideration. In addition, participants will be stratified by age and gender.

The ALFA+ study will start during 2016 and complete follow-up visits will be performed every 3 years. Inclusion and exclusion criteria will be similar to the ALFA parent cohort ones (Table 1), with the addition of the acceptance to all the procedures described below.

2.2.1. Magnetic resonance imaging

Magnetic resonance images will be acquired in a 3.0-T scanner, and the protocol will include a 3D T1-weighted sequence with sub-millimetric isotropic voxel size and clinical T2-weighted sequences oriented along the hippocampal main axis to enable accurate segmentation of the hippocampal subfields. In addition, a high-angular-resolution diffusion imaging sequence and a 9-minute task-free functional MRI sequence will be acquired with isotropic spatial resolution. The ALFA platform will enable the setting up of additional imaging sub-studies including the implementation and validation of MRI research sequences.

2.2.2. Lumbar puncture

CSF will be collected by lumbar puncture between 9 and 12 a.m. in polypropylene tubes. Samples will be processed within 1 hour and will be centrifuged at 4°C for 10 minutes at 2000 g, stored in polypropylene tubes and frozen at −80°C. Core AD biomarkers (namely Aβ42, Aβ40, total Tau, and p tau) and other molecules of interest (such as YKL-40, neurogranin and Aβ oligomers) will be analyzed. Determinations will be carried out in Prof. Kaj Blennow’s laboratory (Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Sweden).
2.3. Amyloid positron emission tomography

A single intravenous dose of 185 MBq of $^{18}$F-Flutemetamol will be administered in a maximum volume of 10 mL with a maximum product mass of 6 ng/mL. The PET procedure, lasting 30 minutes (6 frames of 5 minutes), will start 90 minutes after radiotracer injection.

2.3.1. $^{18}$F-Fludeoxyglucose (FDG) PET

Individuals will receive a single intravenous standard dose of 370 MBq in a volume of 1 to 10 mL. The PET procedure, lasting 30 minutes (6 frames of 5 minutes), will start 45 minutes after radiotracer injection.

2.3.2. Ethical considerations

The ALFA study protocol was approved by the Independent Ethics Committee Parc de Salut Mar Barcelona and registered at Clinicaltrials.gov (Identifier: NCT01835717). It was conducted in accordance with the directives of the Spanish Law 14/2007, of 3rd of July, on Biomedical Research (Ley 14/2007 de Investigación Biomédica). As mentioned before, all participants in the ALFA study accepted the study procedures by signing an informed consent form and had a close relative volunteering to participate in the functional assessment procedure of the participant, who also granted his or her consent. A prerequisite for entering the ALFA+ study (Clinicaltrials.gov Identifier NCT02485730) will be accepting the study procedures and understanding that the CSF results will not be disclosed.

3. Results

To date, we have conducted the baseline visit of the ALFA study that includes, mainly, a sociodemographic, cognitive, and APOE haplotype characterization of the participants.

The 17th September 2012, a press conference was held where the main aims of the ALFA project and inclusion criteria of participants were explained. This resulted in around 5000 persons showing their interest in becoming part of the ALFA parent cohort and, from these, 3102 were visited and assessed for eligibility from April 2013 to November 2014 at the BBRC. Nearly 2000 individuals were not visited due to a variety of reasons, such as not complying with inclusion criteria (e.g. age range), were not reachable, had difficulties to attend the visit, and so forth.

As previously mentioned, and to ensure fulfillment of the study inclusion criteria, the 3102 assessed participants underwent a cognitive screening. Those subjects that fell outside the defined cutoffs (see Methods) were discontinued from the study. Furthermore, their family and personal medical history were also gathered to ensure compliance with the clinical inclusion criteria. In this regard, 359 volunteers were discontinued due to screening failures or voluntary dropouts, which resulted in the final inclusion of 2743 individuals aged between 45 and 74 years, mostly offspring of AD patients that constitute the ALFA parent cohort (a diagram of the participants’ flow is presented in Fig. 1B). Of all the subjects that were excluded due to cognitive performance falling below the established cutoffs (n = 63), 21 obtained a MMSE.

Table 2

Baseline characterization of the ALFA parent cohort participants

| Descriptor | Total (n = 2743) | Group 1 (n = 500) | Group 2 (n = 666) | Group 3 (n = 631) | Group 4 (n = 617) | Group 5 (n = 265) | Group 6 (n = 64) |
|------------|-----------------|------------------|------------------|------------------|------------------|------------------|------------------|
| Age (y)    | 55.8 (6.7)      | 46.7 (1.4)       | 51.4 (1.5)       | 56.3 (1.5)       | 61.5 (1.6)       | 66.1 (1.5)       | 71.2 (1.4)       |
| Men/women (%) | 36.8/63.2     | 33.6/66.4        | 36.9/63.1        | 34.4/65.6        | 42.9/57.1        | 34.3/65.7        | 35.9/64.1        |
| Education (y) | 13.3 (3.5)      | 14.0 (3.3)       | 13.7 (3.4)       | 13.1 (3.4)       | 13.0 (3.7)       | 12.7 (3.6)       | 12.6 (3.5)       |
| GADS-A (0-9)* | 0.6 (1.2)       | 0.7 (1.3)        | 0.7 (1.4)        | 0.6 (1.1)        | 0.4 (0.9)        | 0.5 (1.0)        | 0.4 (0.9)        |
| GADS-D (0-9)* | 0.2 (0.7)       | 0.2 (0.6)        | 0.2 (0.7)        | 0.2 (0.6)        | 0.1 (0.6)        | 0.2 (0.8)        | 0.3 (0.9)        |
| MMSE (0–30) | 29.0 (1.1)      | 29.2 (1.0)       | 29.1 (1.0)       | 29.0 (1.1)       | 29.0 (1.1)       | 28.9 (1.2)       | 28.6 (1.1)       |
| MIS (0-8)  | 7.8 (0.5)       | 7.8 (0.4)        | 7.8 (0.5)        | 7.8 (0.5)        | 7.7 (0.6)        | 7.6 (0.6)        | 7.7 (0.5)        |
| TO-BTII (0–70)* | 70.0 (0.1)   | 70.0 (0.0)       | 70.0 (0.0)       | 70.0 (0.1)       | 70.0 (0.1)       | 70.0 (0.0)       | 70.0 (0.0)       |
| SF (0–10)* | 22.5 (5.1)      | 24.0 (5.0)       | 23.3 (5.1)       | 22.5 (5.0)       | 21.2 (4.9)       | 20.9 (4.8)       | 19.9 (4.2)       |
| MBT-TPR (0–32) | 23.7 (5.3)   | 24.8 (5.0)       | 24.2 (5.4)       | 23.6 (5.0)       | 22.9 (5.7)       | 22.4 (5.0)       | 22.8 (5.1)       |
| Coding-TS (0–135) | 65.8 (14.8) | 73.9 (12.4)      | 70.7 (13.2)      | 65.8 (13.6)      | 60.1 (14.0)      | 54.9 (12.2)      | 51.0 (13.5)      |
| VP (0–26) | 13.3 (4.3)      | 15.0 (4.4)       | 14.2 (4.2)       | 13.3 (4.0)       | 12.0 (3.9)       | 11.6 (3.9)       | 11.0 (3.2)       |
| DS-TS (0–48) | 24.8 (5.2)      | 25.6 (5.3)       | 25.2 (5.1)       | 24.8 (5.4)       | 24.2 (5.0)       | 23.8 (5.1)       | 22.1 (3.6)       |
| Matrix R (0–26)* | 16.6 (4.4)     | 18.7 (4.0)       | 17.8 (4.0)       | 16.4 (4.2)       | 15.4 (4.3)       | 14.5 (4.6)       | 13.0 (4.1)       |
| Similarities (0–36)* | 22.1 (4.7)    | 22.8 (4.6)       | 22.7 (4.6)       | 22.2 (4.6)       | 21.5 (4.7)       | 20.9 (4.9)       | 20.4 (5.1)       |

Abbreviations: GADS-A, Goldberg anxiety scale; GADS-D, Goldberg depression scale; MMSE, Mini-Mental State Examination; MIS, Memory Impairment Screen; TO-BTII, Time-Orientaion subset of the Barcelona Test II; SF, Semantic Fluency (animals); MBT-TPR, Memory Binding Test Total Paired Recall; Coding-TS, Coding Total Score; VP, Visual Puzzles; DS-T, Digit Span Total; Matrix R, Matrix Reasoning.

NOTE. Group 1, 45–49 years; group 2, 50–54 years; group 3, 55–59 years; group 4, 60–64 years; group 5, 65–69 years; group 6, 70–74 years. Possible range scores are indicated in brackets.

*screening tests.

Experimental test battery.
<26, 22 a MIS <6, 14 a SF <12, 3 a MMSE <26 and a MIS <6, one a MIS <6 and a SF <12, and, finally, 2 did not reach the cutoffs for the MMSE, the MIS, and the SF tests. Regarding the cognitive performance of subjects excluded by both cognitive and mood-related criteria (n = 20), 10 obtained a MMSE <26, 7 a MIS <6, one a SF <12, one a MIS <6, and a SF <12 and, finally, one did not reach the cutoffs for the MMSE, the MIS, and the TO-BTII tests.

The ALFA parent cohort members’ mean (SD) age was of 55.8 (6.7) years, 36.8% were men and 63.2% were women with an average years of formal education of 13.3 (3.5) years. Regarding inclusion criteria, the mean MMSE score was of 29.0 (1.1), MIS score of 7.8 (0.5), TO-BTII score of 70.0 (0.1) and SF score of 22.5 (5.1). A baseline characterization of the ALFA cohort members stratified by age groups is summarized in Table 2. Concerning cognitive reserve, participants were grouped into four categories (C1–C4) being C1 the one corresponding to the lowest score and C4 to the highest one [34]. Most of the participants (69%) lay within the highest category (C4), 27% in C3 and only 4% and 1% were categorized as C2 and C1, respectively.

The participants’ family history of AD was recorded during baseline visit. In particular, we registered who, their mother and/or father, had been diagnosed with AD. In this regard, 86.3% of the participants had at least one of their parents that had suffered AD. When considering a more strict family history encoding, it is remarkable that 47.4% of the ALFA study participants had at least one of their parents

Fig. 2. Nonmodifiable risk factors for Alzheimer’s disease (AD). (A) Schematic representation of the ALFA study participants’ parental history of AD before the age of 75 years. Percentage of APOE genotypes in the ALFA parent cohort population (C) compared to the control (B).
that had been diagnosed with AD before the age of 75 years. Specifically, in 2.2% of the volunteers both parents had been diagnosed with AD (at least one of them before the age of 75 years), in 14.3% their father had been diagnosed with AD, and 31.0% of the ALFA study participants’ mother had been diagnosed with AD before the age of 75 years (Fig. 2A).

A higher frequency of the APOE-ε4 allele was found in ALFA parent cohort members than in the general population (19% and 14%, respectively; \(P < .001\)). Specifically, statistically significant differences were found between the APOE-ε3/ε4 and APOE-ε4/ε4 percentages in the ALFA study group and the control (\(P < .001\)). Remarkably, no significant differences were found between the percentage of individuals with the APOEε2/ε4 genotype in the ALFA and control groups (\(P = .241\)). Figure 2 shows the percentage of each of the APOE genotypes found in our population (C) compared to cognitively normal individuals’ percentages taken from the AlzGene database (B). Of 2670 ALFA members whose genotype could be determined, 9 were APOE-ε2/ε2 homozygotes, 167 were APOE-ε2/ε3 heterozygotes, 59 were APOE-ε3/ε4 heterozygotes, 1567 were APOE-ε3/ε3 homozygotes, 782 were APOE-ε3/ε4 heterozygotes and, finally, 86 were APOE-ε4/ε4 homozygotes.

Other variables of interest obtained during the baseline visit were those lifestyles and cardiovascular risk factors that had been previously suggested as modifiable risk factors that may increase or decrease the risk of cognitive impairment and dementia. These include cardiovascular and endocrino-metabolic comorbidities, the participants’ level of physical activity and their smoking habits [35,42]. Cardiovascular comorbidities were self-reported during baseline visit by 28.4% of the subjects, being current hypertension the most prevalent (64.5%). The 42.4% of the study participants self-reported endocrino-metabolic comorbidities: of these, 69.8% reported current dyslipidemia and 9.8% were currently diagnosed with diabetes. 79.8% of the ALFA cohort members had a BMI ≤30 and 73.6% a BMI 25–29.9.

Table 3
Clinical features of the ALFA parent cohort participants

| Descriptor          | General population | ALFA population |
|---------------------|--------------------|-----------------|
|                      | Men    | Women | Men    | Women |
| Hypertension*       | 47.0   | 39.0  | 51.6   | 34.2  |
| Diabetes'           | 13.0   | 10.0  | 6.3    | 3.5   |
| Dyslipidemia'       | 35     | 32    | 35.8   | 29.4  |
| BMI 25–29.9         | 51.0   | 36.0  | 52.3   | 36.5  |
| BMI ≥30             | 29.0   | 29.0  | 24.3   | 18.0  |
| Smoker              | 33.0   | 21.0  | 23.6   | 25.7  |
| Ex-smoker'          | 36.0   | 14.0  | 61.1   | 55.6  |
| Nonsmoker           | 32.0   | 66.0  | 15.3   | 18.7  |

NOTE. Percentages are shown.

*Self-reported hypertension + systolic/diastolic ≥140/90 mm Hg.

1Self-reported.

1For longer than a year. With the exception of BMI 25–29.9, the rest of comparisons were statistically significantly different (\(P < .05\)).

A well-established approach to assess the probability of dementia in late life according to the risk score categories in middle age [35]. Participants risk scores were calculated using both CAIDE statistical models that differ in whether they do not take (model I) or take (model II) the APOE status into consideration. Table 4 shows the percentage of ALFA cohort participants found in each of the CAIDE score ranges as well as their comparison to the general population percentages obtained from the original publication [35].

The ALFA+ longitudinal cohort study will include a subset of 440 participants. It will be enriched in risk factors for AD such as age, family history of the disease, and APOE-ε4 genotype and matched by gender.

4. Discussion

Accumulating data from biomarker and imaging studies support the existence of a preclinical, asymptomatic phase of AD [11,43–47]. In addition, disease-modifying pharmacological interventions on both mild moderate and late-stage AD persons have yet to produce significant clinical benefits [48]. In this scenario, intervention studies and secondary prevention programs on asymmetric at risk individuals emerge as highly relevant, before substantial irreversible neuronal network dysfunction and loss have occurred. To this end, the identification of AD pathology through biomarkers will contribute to the efficient design and performance of preclinical AD trials and prevention studies.

Taking all the above into consideration and with the long-term aim of identifying risk factors that may predispose to suffering or be indicative of AD in asymptomatic individuals, we set out to establish a study of cognitively normal participants, enriched by family history of AD. The ALFA parent cohort is currently composed of 2743 individuals representing a highly valuable research platform. From this population, specific subgroups will be invited to form part of more technological although smaller sized studies. One...
of these, the nested ALFA+ cohort study has been designed to include, besides the already described characterization (neuropsychological evaluation, clinical history, APOE genotyping and lifestyle questionnaires), blood and CSF sampling, FDG and amyloid PET and structural and functional MRI. These procedures will be repeated every 3 years.

Regarding the neuropsychological assessment of the ALFA parent cohort participants, the cognitive screening tests show very similar descriptive data among age groups. However, semantic fluency tests constitute an exception to this trend as they show a tendency to decrease with advancing age (Table 2). This is consistent with previous findings that relate cognitive aging with lower performances in fluency tasks [25,49]. Furthermore, a clear ceiling effect is observable for most of the cognitive tests used for screening purposes: for example, the mean score for the MMSE is of 29 (of 30), 7.8 (of 8.0) for the MIS and 70 (of 70) for the TO-BTII (Table 2). On the other hand, the neuropsychological tests included in the cognitive experimental battery (namely the MBT and the WAIS-IV subtests) are more complex showing no ceiling effects, as shown for the MBT when validated [32,50]. In fact, the MBT was designed with the intention of overcoming some limitations in the sensitivity of the widely used FCSRT in the detection of subtle episodic memory changes due to AD [31]. On the other hand, the initial purpose of the WAIS subtests is to assess intelligence, which, by definition, has a wide range of performance in the population. Indeed, our results confirm that we have established a research platform that is enriched in genetic risk factors for AD. As a consequence, the proportion of patients presenting altered biomarkers, neuroimaging changes and eventually the development of cognitive decline is also expected to be higher, which will be evaluated in the longitudinal assessments and, specifically, in the ALFA+ study.

In summary, the ALFA parent cohort represents a valuable infrastructure of middle age participants representing the whole spectrum of risk that will leverage with different projects and trials to prevent AD. The longitudinal ALFA+ cohort, through deep phenotyping of middle age subjects, is aimed at studying the earliest stages of preclinical AD, which will be useful to understand early pathophysiological changes together with modeling the preclinical stages to develop successful trials.

4.1. Future clinical applications

Throughout the ALFA project, biological and neuroimaging markers present in the AD preclinical phase will be detected, preceding or informing about the presence of brain Aβ deposition. Furthermore, biomarkers used and validated in these studies may constitute endpoints for the construction of large population intervention randomized controlled trials, which will lead to the development of pharmacological

| Score | CAIDE score model I | CAIDE score model II |
|-------|---------------------|---------------------|
|       | Score | CAIDE population, n = 1350 | ALFA population, n = 2302 | Score | CAIDE population, n = 1318 | ALFA population, n = 2247 |
| 0-5   | 29.7  | 45.0  | 0-5   | 22.2  | 29.2  | 6-7   | 20.0  | 29.1  | 6-8   | 27.5  | 41.1  |
| 6-9   | 23.1  | 18.4  | 9-10  | 20.0  | 17.5  | 10-11 | 18.2  | 6.2   | 11-12 | 17.2  | 9.3   |
| 12-15 | 9.0   | 1.3   | 13-18 | 13.1  | 2.9   |

NOTE. *P < .001. Percentages are shown.
and nonpharmaceutical interventions targeting individuals at risk for AD.

Acknowledgments

The authors express their most sincere gratitude to the ALFA project volunteers, without whom this research would have not been possible. The research leading to these results has received funding from “la Caixa” Foundation. Additional funding was obtained from: Fondo de Investigación Sanitaria (FIS), Instituto de Salud Carlos III under grant PI12/00326. Biological samples are stored at the MARBiobanc (Barcelona) that receives funding from the Instituto de Salud Carlos III FEDER (RD09/0076/00036). Juan D. Gispert holds a “Ramón y Cajal” fellowship (RYC-2013-13054). The authors are indebted to the collaborators who have supported our team in the design and implementation of the ALFA project (Carme Junquera, Raquel Sánchez-Valle, Jesús Pujoł, Carmen Ayuso, Jordi Sunyer, Jordi Alonso, and Jordi Peña-Casanova), and the scientific international committee (Bruno Dubois, Zaven Khachatourian, Javier Nieto, Ronald Petersen, Hugo Vanderstichele, and Bengt Winblad). We thank Neil Forrest for carefully proof reading this article and the reviewers of this article for their valuable comments. In memory of Mrs. Maria Thos i Negre, the authors would like to express their gratitude for her donation to the Pasqual Maragall Foundation for research on Alzheimer’s prevention.

RESEARCH IN CONTEXT

1. Systematic review: The authors reviewed the literature using traditional sources. Cohort studies aimed at identifying early pathophysiological events of Alzheimer’s disease (AD) and developing prevention programs are cited throughout the article.

2. Interpretation: The ALFA project consists of the ALFA registry, the ALFA parent cohort, and the nested ALFA+ study. The parent cohort includes 2743 participants and is enriched for family history of AD and APOE-ε4 genotypes.

3. Future directions: The ALFA parent cohort represents a valuable infrastructure of middle age participants representing the whole spectrum of risk that will leverage with different projects and trials to prevent AD. The longitudinal ALFA+ cohort, through deep phenotyping of middle age subjects, will be useful to understand early pathophysiological changes together with modeling the preclinical stages to develop successful trials.

References

[1] Takizawa C, Thompson PL, van Walsem A, Faure C, Maier WC. Epidemiological and economic burden of Alzheimer’s disease: a systematic literature review of data across Europe and the United States of America. J Alzheimers Dis 2015;43(3):1271–84.
[2] World Alzheimer Report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International (ADI); 2015.
[3] Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1988 to 2014. J Intern Med 2014; 275:251–83.
[4] Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perrett-Liaudet A, et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: a consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement 2014;10:808–17.
[5] Bernard C, Helmer C, Diharregaruy B, Amieva H, Auriacombe S, Dartigues JF, et al. Time course of brain volume changes in the preclinical phase of Alzheimer’s disease. Alzheimers Dement 2014;10:143–1511.
[6] Ikeda M, Tanabe H, Nakagawa Y, Kazui H, Oi H, Yamazaki H, et al. MRI-based quantitative assessment of the hippocampal region in very mild to moderate Alzheimer’s disease. Neuroradiology 1994;36:7–10.
[7] Landau SM, Mintun MA, Joshi AD, Koepppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578–86.
[8] Ewers M, Insel PS, Stern Y, Weiner MW. Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology 2013; 80:1194–201.
[9] Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013;9(5 Suppl):S72–83.
[10] Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012;79:1636–44.
[11] Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013;12:957–65.
[12] Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherr B, et al. Prevention trials in Alzheimer’s disease: an EU-US task force report. Prog Neurobiol 2011;95:594–600.
[13] Changing the Trajectory of Alzheimer’s Disease: How a Treatment by 2025 Saves Lives and Dollars Alzheimer’s Association; 2010.
[14] Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, et al. Designing drug trials for Alzheimer’s disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 2013;9:438–44.
[15] Sager MA, Hermann B, La Rue A. Middle-aged children of persons with Alzheimer’s disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer’s Prevention. J Geriatr Psychiatry Neurol 2005;18:245–9.
[16] Coats M, Morris JC. Antecedent biomarkers of Alzheimer’s disease: the adult children study. J Geriatr Psychiatry Neurol 2005;18:242–4.
[17] Ritchie CW, Wells K, Ritchie K. The PREVENT research programme—a novel research programme to identify and manage midlife risk for dementia: the conceptual framework. Int Rev Psychiatry 2013;25:748–54.
[18] Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S. Development of interventions for the secondary prevention of Alzheimer’s dementia: the European Prevention of Alzheimer’s Dementia (EPAD) project. Lancet Psychiatry 2016; 3:179–86.
[19] Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.

[20] Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Hernandez G, et al. Clinical validity of the ‘mini-mental state’ for Spanish speaking communities. Neuropsychologia 2001;39:1150–7.

[21] Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, et al. Screening for dementia with the memory impairment screen. Neurology 1999;52:231–8.

[22] Bohm P, Pena-Casanova J, Gramunt N, Manero RM, Terron C, Quinones-Ubeda S. Psychology. Barcelona: Ramon Llull University; 2009.

[23] Quinones-Ubeda S. The Clinical Dementia Rating (CDR): current version and normative data and discriminant validity. Neurology 2005;20:402–11.

[24] Monton C, Perez-Echeverria MJ, Campos R, Garcia Campayo J, Lobo A. Spanish Multicenter Neurol (Paris) 1970;123:17–22.

[25] Castellvi M, et al. Cognitive reserve questionnaire. Scores obtained among middle aged people: a longitudinal, population-based study. Rev Neurol (Paris) 1997;278:1349–56.

[26] Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015–22.

[27] Buschke H. The rationale of the Memory Binding Test. In: Nilsson LG, Ohta N, eds. Dementia and Memory. New York: Psychology Press; 2015:55–72.

[28] Ramos AM, Hecaen H. Role respectif des atteintes frontales et de la lateralisation lesionnelle dans les deficits de la fluence verbale. Rev Neurol (Paris) 1970;123:17–22.

[29] Pena-Casanova J, Quinones-Ubeda S, Gramunt-Fombuena N, Quinones-Ubeda S. Psychology. Barcelona: Ramon Llull University; 2009.

[30] Blesa R, Pujol M, Aguilar M, Santacruz P, Bertran-Serra I, Monton C, Perez Echeverria MJ, Campos R, Garcia Campayo J, Lobo A. Spanish Multicenter Neurol (Paris) 1970;123:17–22.

[31] Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015–22.

[32] Buschke H. The rationale of the Memory Binding Test. In: Nilsson LG, Ohta N, eds. Dementia and Memory. New York: Psychology Press; 2015:55–72.

[33] Hassenstab J, Ruvolo D, Jasielec M, Xiong C, Grant E, Morris JC. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. Neurology 2014;82:1760–7.

[34] Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012;11:1048–56.

[35] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013;12:357–67.

[36] Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6:37.

[37] Lucas JA, Ivnik RJ, Smith GE, Bohac DL, Tangalos EG, Graff-Radford NR, et al. Mayo’s older Americans normative studies: category fluency norms. J Clin Exp Neuropsychol 1998;20:194–200.

[38] Morrow EC, Betensky RA, Heedten T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014;82:1760–7.

[39] Haro JM, Palacin C, Vilagut G, Martinez M, Bernal M, Luque I, et al. Prevalence of mental disorders and associated factors: results from the ESEMed-Spain study. Med Clin (Barc) 2006;126:445–51.

[40] Eysenck H, Eysenck SB. EPQ-R. Cuestionario revisado de personalidad de Eysenck. 10th ed. Madrid: TEA ediciones; 2001.

[41] Grau M, Elosua R, Cabrera de Leon A, Guembe MJ, Baena-Diez JM, Vega Alonso T, et al. Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study. Rev Esp Cardiol 2011;64:295–304.

[42] Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47.

[43] Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012;367:795–804.

[44] Knoopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe V, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576–82.

[45] Grau M, Elosua R, Cabrera de Leon A, Guembe MJ, Baena-Diez JM, Vega Alonso T, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014;82:1760–7.

[46] Leibman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012;11:1048–56.

[47] Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013;12:357–67.

[48] Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6:37.

[49] Lucas JA, Ivnik RJ, Smith GE, Bohac DL, Tangalos EG, Graff-Radford NR, et al. Mayo’s older Americans normative studies: category fluency norms. J Clin Exp Neuropsychol 1998;20:194–200.

[50] Gramunt N, Sanchez-Benavides G, Buschke H, Lipton RB, Masramon X, Gispert JD, et al. Psychometric Properties of the Memory Binding Test: Test-Retest Reliability and Convergent Validity. J Alzheimers Dis 2016;50:999–1010.

[51] Hassenstab J, Ruvolo D, Jasielec M, Xiong C, Grant E, Morris JC. Absence of practice effects in preclinical Alzheimer’s disease. Neuropsychology 2015;29:940–8.

[52] Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, et al. Risk of dementia among white and African American relatives of patients with Alzheimer’s disease. JAMA 2002;287:329–36.

[53] Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: the REVEAL study. Genet Med 2004;6:192–6.

[54] Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349–56.